AZIS R. DABAS
Explore
Contact
Research & executive judgment

Public health and nutrition economics / OCTOBER THESIS 04

Food-as-Medicine Contracts Should Buy Nutritional Persistence, Not Enrollment

The newest trials make the purchase decision more specific. A culturally tailored heart-failure intervention improved short-term utilization outcomes, while other trials did not establish every assumed benefit. Buyers should contract for a defined clinical population, usable nutrition and sustained follow-through, with an evaluation design that can distinguish incremental value from improvement that would have happened anyway.

THE THESIS

Food-as-medicine becomes a defensible healthcare investment when the contract makes delivered nutrition, continued use and accountable clinical follow-through observable; enrollment alone cannot establish an incremental health or financial return.

Evidence trail
3 scholarly sources
4 attributed sources
Research cutoff
October 7, 2026

Original executive analysis of three fetched Consensus trial records, verified against primary publication records, and federal nutrition principles. Evidence checked through October 7, 2026. The proposed contracting design and economic logic are author analysis, not trial findings or a claim of guaranteed savings. This is independent executive analysis of attributed evidence; it is not an original clinical study or a peer-reviewed journal publication.

Editorial revision: . Original publication and source dates are retained.

Three sculpted paths meet in a sheltered stone courtyard.
Editorial illustration

Separate services need a shared path to completion.

01 / THE ARGUMENT

The next contract needs a narrower promise

An employer, health plan or accountable provider purchasing food-as-medicine needs to define which patients receive which intervention, whether they can use it, and which outcome the contract finances. My proposed unit of purchase is a completed period of appropriate nutritional support with documented follow-up. Enrollment starts that period; delivery, continued use and follow-up determine whether the contracted service was provided.

The September 2026 MUTTON-HF publication supplies important, specific evidence: among 206 patients with heart failure in rural Navajo Nation, a culturally and medically tailored intervention reduced the 90-day composite of hospitalization or emergency-department use relative to usual dietary advice, with a relative risk of 0.72 and a 95% confidence interval of 0.54–0.96. This supports that intervention in that population; it does not establish the return for every nutrition benefit. [1]

02 / THE ARGUMENT

Evidence heterogeneity should change procurement

Contrasting results sharpen the commercial question. Doyle and colleagues' randomized study of an intensive grocery and care-support program found no significant between-group HbA1c improvement at six months, despite greater preventive-care engagement. The result cautions against crediting a vendor for all improvement observed after enrollment. [2] The 2026 FAME-F trial also found no significant advantage for household rather than individual meal provision on its primary diet-quality measure, or for dedicated drivers rather than commercial shipping on its loneliness measure. Its small size and wide intervals leave meaningful uncertainty. [3]

My procurement inference is to price the intervention's components separately before buying a bundle. Meal quantity, household support, clinical nutrition expertise, delivery logistics and human contact may solve different problems. A buyer should require a reason for each component, then test the components that drive its own expense and patient experience. Neither a positive trial nor a null finding warrants treating all implementations as interchangeable.

03 / THE ARGUMENT

Persistence is an operating pathway

The proposed pathway begins with clinical eligibility and a practical nutrition assessment: storage, preparation, household sharing, preferences and the patient's ability to receive deliveries. A dietitian-approved plan then connects the vendor to the treating team. Delivery confirmation should distinguish receipt from usability; a repeated refusal, refrigeration problem or mismatch with the care plan should trigger a person with authority to change the service. These are operating design choices rather than new scientific claims.

I would track a nutrition episode from authorization through first usable delivery, continued participation, review and transition. The handoff at the end matters commercially: a temporary intervention needs an agreed destination, whether ordinary food access, continued covered support or a different clinical service. Federal Food Is Medicine principles emphasize culturally appropriate design, community partnerships and local capacity. Those principles inform program design but do not by themselves create coverage or a payment entitlement. [4]

04 / THE ARGUMENT

Build economics around incremental value

For an illustrative buyer model, expected net value equals eligible episodes multiplied by participation, incremental outcome benefit and the buyer's realizable financial value, less food, logistics, clinical follow-up, implementation and evaluation costs. Each input must have a documented definition and a sensitivity range. This is a proposed planning equation, not a published savings estimate. Patient food security and quality of life deserve their own measures even when a purchaser cannot monetize them.

The evaluation should begin before outreach. Prefer random allocation or a defensible phased rollout when feasible; otherwise predefine a comparison cohort, eligibility dates, baseline risk and concurrent medication changes. Analyze everyone assigned or offered the intervention as well as participants, and report missing follow-up. Claims-based savings need adequate maturation and an explicit attribution method. A fall in utilization among selected completers is insufficient grounds for a shared-savings invoice.

05 / THE ARGUMENT

Use the contract to preserve learning

I would separate payment for reliable service from payment for a demonstrated incremental outcome. The service obligation covers agreed food, delivery, appropriate support and recovery when the pathway fails. An outcome payment requires a reproducible comparison and reconciliation method. Blending the two can make the vendor responsible for factors it cannot control while giving the buyer insufficient visibility into the work it purchased.

The contract should also guard against selecting only easy-to-serve participants. Report the full eligible or offered population, reasons for nonparticipation and the distribution of delivery failures. Allow clinically appropriate substitutions and changes rather than rewarding persistence with an unsuitable intervention. Pay community partners on a schedule that supports their capacity. Where outcomes remain uncertain, a limited cohort with funded evaluation buys information without requiring those partners to finance a speculative savings guarantee.

The executive decision is therefore whether a particular nutritional pathway merits expansion, redesign or termination. An early win may be reliable access and lower food insecurity; a later finding may establish a clinical benefit. Keep those findings separate. Scale when the intervention fits the population, patients continue using it, the care team can act on exceptions and the economics survive conservative assumptions. That standard protects both the scientific proposition and the credibility of the business case.

FROM EVIDENCE TO ALLOCATION

The operating and investment case

My proposed operating design. These decisions and evaluation criteria are not outcomes established by the cited studies.

Decision
Commission a bounded, clinically defined nutrition episode with an evaluation plan before expanding a food benefit across a covered population.
Accountable owner
Health-plan population-health executive with a medical director, registered dietitian lead, finance partner and community-provider representative.

The delivery sequence

  1. Define eligibility, covered services and comparator before outreach
  2. Assess clinical and practical nutrition requirements
  3. Confirm first usable delivery and dietitian-approved fit
  4. Monitor continued participation and route exceptions to an accountable person
  5. Review clinical and patient-reported outcomes
  6. Reconcile service payments separately from evaluated outcome value

The economics

Illustrative planning model: eligible episodes × participation × incremental outcome benefit × realizable buyer value, minus the complete food, delivery, clinical, implementation and evaluation cost. Do not use an external trial's relative risk as the local savings assumption without validation.

The measures that govern expansion

  • Time to first usable delivery
  • Usable deliveries as a share of scheduled deliveries
  • Participation persistence and reasons for withdrawal
  • Food-security and patient-experience change
  • Predefined clinical outcome relative to comparator
  • Total episode cost and conservatively attributed net value

Stop or redesign when

Pause expansion if food is regularly unusable, clinical exceptions remain unresolved, follow-up data cannot support evaluation, or the business case depends on attributing all pre/post improvement to the intervention.

THE EVIDENCE LEDGER

What supports the argument

Study findings, policy requirements and market signals support different claims. Their boundaries remain visible.

[1] peer-reviewed · September 1, 2026

An Indigenous Food Is Medicine Intervention: The MUTTON-HF Randomized Clinical Trial

Design or status
Pragmatic open-label randomized trial at two Indian Health Service sites; 206 participants; 90-day primary endpoint.
Verified finding
The intervention reduced the hospitalization/ED composite relative to usual advice (RR 0.72, 95% CI 0.54–0.96).
Boundary
Short follow-up and a specific rural Indigenous heart-failure population limit generalization and do not establish local payer savings.

[2] peer-reviewed · December 26, 2023

Effect of an Intensive Food-as-Medicine Program on Health and Health Care Use: A Randomized Clinical Trial

Design or status
Randomized wait-list trial of patients with diabetes and food insecurity in one rural and one urban health-system clinic.
Verified finding
The adjusted between-group six-month HbA1c difference was −0.10 percentage points (95% CI −0.46 to 0.25); preventive-care engagement increased.
Boundary
A particular intensive grocery and support program; missing laboratory follow-up and its setting limit extrapolation to other nutrition interventions.

[3] peer-reviewed · April 1, 2026

Designing Medically Tailored Meal Interventions: The Food as Medicine for Families (FAME-F) Factorial Randomized Clinical Trial

Design or status
2×2 factorial randomized comparative-effectiveness trial; 93 New England participants receiving meals for 12 weeks.
Verified finding
No significant differences were detected for the primary diet-quality comparison or loneliness comparison between intervention designs.
Boundary
Small sample, wide confidence intervals and no no-meal control; this is not evidence that meals have no benefit or that delivery methods are equivalent.

[4] policy · September 14, 2024

Our Principles for Food Is Medicine

Design or status
Federal program principles; date is the page's last-reviewed date.
Verified finding
The framework emphasizes culturally appropriate nutrition, cross-sector partnerships and investment in under-resourced community capacity.
Boundary
Program principles are neither coverage authorization nor an estimate of causal clinical or financial impact.

FOLLOW THE SOURCE

Sources and editorial method

Selected evidence was reviewed through October 7, 2026. Numbered references connect claims to their underlying records. Economic mechanisms and business cases are my analysis unless a source is cited. The review is selective; publication dates retain the precision available in the source.

  1. An Indigenous Food Is Medicine Intervention: The MUTTON-HF Randomized Clinical Trial

    Lauren A. Eberly, Carmen George, Sharon Sandman, Denee Bex, Karianne Jones, Asia Yazzie, Leah Gray, Larissa Morgan, Ada Tennison, Conor Williams, Matt Chandra, Rebecca Wickre, Bennett Wickre, Mackenzie Bolas, Remi Welbel, Delaney Ignace, Benjamin Feliciano, Stacy Hammer, DezBaa Damon-Mallette, Erica Lindsey, Paula Mora, Aijun Ye, Maricruz Merino, Enrique F. Schisterman, Sonya S. Shin. JAMA Internal Medicine. . peer-reviewed.

  2. Effect of an Intensive Food-as-Medicine Program on Health and Health Care Use: A Randomized Clinical Trial

    Joseph Doyle, Marcella Alsan, Nicholas Skelley, Yutong Lu, John Cawley. JAMA Internal Medicine. . peer-reviewed.

  3. Designing Medically Tailored Meal Interventions: The Food as Medicine for Families (FAME-F) Factorial Randomized Clinical Trial

    Seth A. Berkowitz, Jacqueline Nguyen, Colleen Dagley, Salma Ali, Myklynn LaPoint, Patricia Knoepp, Jean Terranova. Circulation: Population Health and Outcomes. . peer-reviewed.

  4. Our Principles for Food Is Medicine

    U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. HHS Food Is Medicine initiative. . policy.

Study authors retain credit for their work. Researcher affiliations and publisher names do not imply affiliation with or endorsement of this analysis.

FROM EVIDENCE TO EXECUTIVE ACTION

What should this change in your organization?